Pfizer Inc and BioNTech SE announced today that they have initiated mid-level trials of a modified Covid-19 vaccine that targets both the original variants and the BA.2 Omicron sub-variant.
The vaccine is in an initial proof-of-concept study to gather more data (https://bit.ly/3veWPKn).
The BA.4 and BA.5 subvariants combined are estimated to account for nearly 95% of the subvariants in circulation in the United States in the week ending July 23.
The US Food and Drug Administration last month asked companies to make vaccines that target the BA.4 and BA.5 subvariants, which are currently the dominant ones, for a possible booster in the fall.
Source: RES-MPE
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
